Implications of the COVID-19 pandemic in eliminating trachoma as a public health problem

Trans R Soc Trop Med Hyg. 2021 Mar 6;115(3):222-228. doi: 10.1093/trstmh/traa170.

Abstract

Background: Progress towards elimination of trachoma as a public health problem has been substantial, but the coronavirus disease 2019 (COVID-19) pandemic has disrupted community-based control efforts.

Methods: We use a susceptible-infected model to estimate the impact of delayed distribution of azithromycin treatment on the prevalence of active trachoma.

Results: We identify three distinct scenarios for geographic districts depending on whether the basic reproduction number and the treatment-associated reproduction number are above or below a value of 1. We find that when the basic reproduction number is <1, no significant delays in disease control will be caused. However, when the basic reproduction number is >1, significant delays can occur. In most districts, 1 y of COVID-related delay can be mitigated by a single extra round of mass drug administration. However, supercritical districts require a new paradigm of infection control because the current strategies will not eliminate disease.

Conclusions: If the pandemic can motivate judicious, community-specific implementation of control strategies, global elimination of trachoma as a public health problem could be accelerated.

Keywords: COVID-19; control; elimination; mass drug administration; mathematical modelling; trachoma.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / therapeutic use*
  • COVID-19 / epidemiology*
  • Communicable Disease Control / organization & administration*
  • Humans
  • Mass Drug Administration
  • Neglected Diseases / epidemiology
  • Neglected Diseases / prevention & control
  • Pandemics
  • Prevalence
  • Public Health
  • SARS-CoV-2
  • Trachoma / epidemiology*
  • Trachoma / prevention & control*

Substances

  • Anti-Bacterial Agents
  • Azithromycin